Fulcrum Therapeutics Inc (FULC)

NASD · Healthcare · Biotechnology · USA

Fulcrum Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical firm creating oral medicines for patients with rare genetic disorders. Its lead candidate, pociredir, is in clinical development for sickle cell disease by increasing fetal hemoglobin production. The company uses proprietary discovery approaches to identify and validate cellular targets that modulate gene expression for rare hereditary conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Fulcrum Therapeutics Inc stock.

Our verdict on FULC

Not valued: We cannot value this company yet.

ETFs with the most weight in FULC

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than FULC in Biotechnology

129 more in this industry show a wider margin of safety.

Is FULC undervalued or overvalued?

We do not publish a verdict on FULC yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of FULC?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.